Summary
50 / 100 · Bulios Score
What speaks for it
- Revenue grew by 16% a year over the last 3 years.
- The share price is below the Bulios Fair Price.
What to watch
- Repaying its net debt would take 3.7 years of operating profit.
- Out of every 100 JPY of revenue, only 2.9 JPY is left as net profit.
- It earns only 2.8 JPY a year on every 100 JPY of invested capital.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 24.3 JPY for 1 JPY of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (JPY)
Diluted EPS (JPY)
- Analyst estimate
Revenue grew by 19% a year over 5 years. Over the last 3 years it grew by 16% a year. For the next fiscal year analysts expect revenue to grow by 7.8%. Earnings per share grew by 6.8% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 JPY of revenue goes
- Cost of sales 64 JPY
- Sales and administration 28 JPY
- Taxes and other 5.8 JPY
- Net profit 2.9 JPY
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 10 JPY
Out of every 100 JPY of revenue, 2.9 JPY is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 52.2 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, stretched- Yield
- 1.96%
- Paid out of profit
- 48%
- Raised in a row
- 1 year
You receive $0.51 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.